COVID-19 infection and subsequent psychiatric morbidity, sleep problems and fatigue: analysis of an English primary care cohort of 226,521 positive patients
Covid19-Sources
Can mRNA-based COVID-19 vaccines cause prion disease or Alzheimer’s? | Science-Based Medicine
A third dose of the AstraZeneca vaccine is found to boost immune response.
How a COVID-19 infection changes blood cells in the long run -- ScienceDaily
Alpha könnten wir mit Impfen in den Griff bekommen. Aber Delta wohl nicht? (Modellrechnungen) – Dirk Paessler's Personal Blog
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine | NEJM
COVID-19 and balancing the risks: The vaccine or the virus | Science-Based Medicine
Asian Pacific Journal of Tropical Medicine - Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial : Download PDF
Clinical and Virological Features of SARS-CoV-2 Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta) by Sean Wei Xiang Ong, Calvin J. Chiew, Li Wei Ang, Tze-Minn Mak, Lin Cui, Matthias Paul HS Toh, Yi Ding Lim, Pei Hua Lee, Tau Hong Lee, Po Ying Chia, Sebastian Maurer-Stroh, Raymond Tzer Pin Lin, Yee-Sin Leo, Vernon J. Lee, David Chien Lye, Barnaby E. Young :: SSRN
Frontiers | Retinal microcirculation as correlate of a systemic capillary impairment after SARS-CoV-2 infection | Medicine
Retraction: Walach et al. The Safety of COVID-19 Vaccinations—We Should Rethink the Policy. Vaccines 2021, 9, 693
Israel: Nein, die Covid-19-Impfung erzeugt keine 40 Mal höhere Sterberate
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study
Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: a time series study based on national surveillance data
Using Genomic Concordance to Estimate COVID-19 Transmission Risk Across Different Community Settings in England 2020/21 by Cong Chen, Simon Packer, Charlie Turner, Charlotte Anderson, Gareth Hughes, Obaghe Edeghere, Isabel Oliver, Ewan Birney :: SSRN
Frontiers | T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis | Immunology
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans | Nature
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM
Pseudouridin – Wikipedia
COVID-19: Auswirkungen auf das zentrale und periphere Nervensystem | SpringerLink
Coronavirus weltweit: AstraZeneca testet abgewandelten Impfstoff gegen Beta-Variante
First COVID case could have hit China in October 2019: UK study
Coronavirus (Covid-19) — NEJM
Ivermectin
Diese Entdeckung muss um die Welt gehen! - Sucharit Bhakdi und Karina Reiss im Gespräch
Children with long covid
(3) Eric Feigl-Ding auf Twitter: "When will vaccines for children be available? ➡️ Pfizer anticipates having initial results of lower-dose Phase 2/3 trials in September for 5- to 11-year-old kids; results for kids 2-<5 shortly after; kids 6-<24 months old in October or November. #COVID19 https://t.co/F1dEYZNhZt" / Twitter